Insulet, Tandem Diabetes drop as weight loss drugs impact insulin use
Tatiana/iStock via Getty Images
Insulet Corporation (NASDAQ:PODD) and Tandem Diabetes (NASDAQ:TNDM) were among the notable decliners on Thursday after data indicated that popular weight loss drugs such as Ozempic and Wegovy can cut the need for insulin injections in people with diabetes.
The findings come at a time when investigators are pursuing clinical trials to see if the blockbuster drugs, known as GLP-1 agonists, marketed by Novo Nordisk (NVO) (OTCPK:NONOF), can bring health benefits other than weight loss.
According to results from a small study published in the New England Journal of Medicine, the treatments, also known as semaglutide in generic terms, sharply reduced or even eliminated the need for insulin injections in patients with type 1 diabetes.
"If these findings are borne out in larger studies over extended follow-up periods, it could possibly be the most dramatic change in treating Type 1 diabetes since the discovery of insulin in 1921," lead investigator Paresh Dandona, MD, said.
Dandona formerly headed the Division of Endocrinology in the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo.
Insulet (TNDM) and Tandem Diabetes Care (TNDM), along with their larger rival Medtronic (NYSE:MDT), market continuous insulin delivery systems for people with insulin-dependent diabetes.
The companies' insulin pumps are integrated with continuous glucose monitors (CGM) from the likes of Abbott (ABT) and DexCom (DXCM).
Remarks made by Insulet (PODD) after the study's publication didn't help either. At the Wells Fargo Healthcare Conference on Thursday, the company's CEO, James Hollingshead, cited the potential impact of GLP-1s on the insulin market.
"What we might see is GLP-1s impacting the time to progression to -- this is what people are worried about from looking at our business, time to progression on the insulin therapy," Hollingshead said.
However, he ruled out major concerns, arguing that insulin prescriptions remained flat in the U.S. despite the recent surge in GLP-1 uptake. "And whatever impact on progression, the insulin need is out there, is baked in the cake already with those GLP-1s," Hollingshead added.

More on Medtronic, Insulet, etc.

Compare metrics for MDT to PODD, TNDM

Medtronic plc (MDT) Wells Fargo 2023 Healthcare Conference (Transcript)
Medtronic: The Crossroads Of Its Growth Trajectory
Tandem Diabetes: Cash Flow And Profitability Trends A Drag On Equity Performance, Reiterate Hold
Medtronic Q1 2024 Earnings Review: Management Placates The Market
Medtronic: The Tide Is Turning
Insulet: Losing More Weight

Medtronic plc (MDT) Q1 2024 Earnings Call Transcript
Medtronic plc 2024 Q1 - Results - Earnings Call Presentation
DexCom cites rising glucose monitor use amid weight loss therapy
Insulet gains amid winning TRO in dispute with EOFlow, CEO insider buy
Insulet spikes as CEO buys over $1M shares
Medtronic gets EU approval for Inceptiv spinal cord stimulator
Medtronic slips as FDA panel votes against blood pressure treatment
Medtronic raises guidance as Q1 results exceed forecasts
Medtronic Non-GAAP EPS of $1.20 beats by $0.09, revenue of $7.7B beats by $140M
Can Medtronic beat negative forecasts with Q1 results?